Protalex — Investor Presentation (June 2014)
25 slides from Protalex's investor presentation, Jun 23, 2014
Slide 1: Protalex
PRTX PROTALE
Slide 2: Forward-Looking Statement
Forward - Looking Statement Statements made in this presentation stating the Company ’ s beliefs, intentions, and expectations are forward - looking statements. The company ’ s actual results could differ materially from those projected. Additional information is contained in the company ’ s SEC fil
Slide 3: Protalex, Inc.
Protalex , Inc. Biotechnology company focused on autoimmune diseases Public company, ticker is PRTX, market capitalization approximately $250 mm Lead product: PRTX - 100 ▪ Staphylococcal protein A, a natural protein isolated from cultured bacteria ▪ Safe and well - tolerated in four human clin
Slide 4: Protalex Key Team Members
Protalex Key Team Members Arnold P Kling – President, Director; Principal of Niobe Ventures, LLC, experienced investor in and manager of early stage technology companies Kirk M Warshaw – CFO, Director; experienced in finances of development stage company James W Dowe III – Vice - Chair of SAB;
Slide 5: Background
PRTX - 100 Background Highly purified Staphylococcus aureus protein A (SPA) SPA is a superantigen ▪ SPA acts as an immunological “disguise” and increases bacterial virulence ▪ Purified SPA binds antibodies, forming discrete immune complexes, and immune cells of monocyte lineage, attenuating thei
Slide 6: Animal Studies of PRTX-100
Animal Studies of PRTX - 100 PRTX - 100 reduces footpad swelling in the murine CIA model of arthritis PRTX - 100 inhibits platelet phagocytosis by human macrophages in vitro — model for ITP, an orphan disease PRTX - 100 is not immunosuppressive like anti - TNFs • Pretreat w drug • Challenge w
Slide 7: Autoimmune Disease Market Opportunity
Autoimmune Disease Market Opportunity RA biologics current market value exceeds $18 B and is growing RA market disruptions envisioned ▪ PFE’s Xeljanz ( tofacitinib ) oral drug recently approved ▪ Biosimilars to anti - TNFs and anti - CD20s in development Current biologics are expensive to prod
Slide 8: Clinical Experience
PRTX - 100 Clinical Experience 2005 – IND filed for RA 2006 – Phase 1 study completed 2007 – Second Phase 1 using PRTX - 100 with improved production/CMC processes 2010 - 11 – Phase 1b Study (PRTX - 100 - 103) in South Africa; presented at ACR Annual Meeting in November, 2012 November 2012
Slide 9: 103: Study Objectives
PRTX - 100 - 103: Study Objectives Primary ▪ Assess safety and tolerability of iv PRTX - 100 weekly x 4 doses Secondary ▪ Assess immunogenicity after ≥3 doses ▪ Determine PK and estimate of PRTX - 100 plasma exposure after first and fourth dose ▪ Determine whether a relationship exists between i
Slide 10: 103: DAS28 < 3.2
PRTX - 100 - 103: DAS28 < 3.2 0 5 10 15 20 25 30 PRTX-100 Placebo % of patients with DAS28 < 3.2 at 6 and 10 weeks Day 42 Day 70 3/29 6/29 0/8 0/8 10 Protalex , Inc.
Slide 11: 103: Summary
PRTX - 100 - 103: Summary PRTX - 100 was well tolerated ▪ 3 mild to moderate infusion reactions, no SAEs related to study drug ▪ Anti - PRTX - 100 antibodies elicited in majority of patients but neither incidence nor titer was related to dose ▪ Patients with antibody response showed increased clea
Slide 12: 104: Overview
PRTX - 100 - 104 : Overview Multi - center US study initiated 4Q12. Phase 1b randomized, multiple - dose, placebo - controlled, dose - escalation study of PRTX - 100 in adults with active RA on MTX 41 patients dosed in four dose - escalating cohorts, starting at 1.50 m g/kg, with fifth cohort to
Slide 13: 104: Study Design
PRTX - 100 - 104: Study Design Patients with RA: ▪ ≥ 4 swollen and ≥ 5 tender joints (28 joint count) ▪ Positive RF or anti - CCP ▪ Stable dose of MTX or leflunomide Treatment ▪ Randomized in blocks (3:1) ▪ PRTX - 100 at 1.5, 3.0, 6.0, or 12.0 µg/kg iv, five weekly doses Measurements ▪ PK at 1
Slide 14: 104: Patient Demographics
PRTX - 100 - 104: Patient Demographics 14 PRTX - 100 dose 1.5 µg/kg 3.0 µg/kg 6.0 µg/kg 12 µg/kg All Placebo No. of patients a 6 9 9 5 29 8 Mean age, years (SD) 61.2 (13.3) 57.6 (11.8) 63.3 (9.7) 62.6 (6.8) 61.1 (10.3) 59.9 (9.4) Age range, years 47 – 76 30 – 72 42 – 71 51 – 72 30 – 72 46 – 71 Male,
Slide 15: 104: Overall Safety
PRTX - 100 - 104: Overall safety Doses of 1.5 to 12 µg/kg PRTX - 100 appeared well - tolerated and demonstrated no dose - limiting toxicities. No treatment - related SAEs and no requirement for expedited reports to FDA Most commonly reported AEs were fatigue and flare of RA symptoms of mild to
Slide 16: 104: Promising Effects on Measures of Disease Activity
PRTX - 100 - 104: Promising Effects on Measures of Disease Activity Results are not inconsistent with therapeutic activity PRTX - 100 - treated patients had a higher categorical response rate for ACR, CDAI, and DAS28 - CRP at days 29, 57, 85, and 113 vs placebo 43% of PRTX - 100 treated patien
Slide 17: 104: RA Disease Activity
PRTX - 100 - 104: RA Disease Activity 17 PRTX - 100 dose Disease activity endpoint, a % of patients 1.5 µg/kg (n=6) 3.0 µg/kg (n=9) 6.0 µg/kg (n=9) 12.0 µg/kg (n=5) All (n=29) Placebo ( n =8) ACR20 CRP day 29 33.3 33.3 22.2 40.0 31.0 12.5 ACR20 CRP day 57 50.0 50.0 33.3 80 50.0 37.5 ACR20 CRP day 85
Slide 18: 104: DAS28 categorical analysis — all PRTX-100 vs. Placebo
PRTX - 100 - 104: DAS28 categorical analysis — all PRTX - 100 vs. Placebo 18 DAS28<2.6 DAS28<3.2 Day MTX MTX+SPA MTX MTX+SPA 22 14.3% 11.1% 14.3% 18.5% 29 12.5% 21.4% 12.5% 35.7% 57 25.0% 37.0% 50.0% 51.8% 85 14.3% 17.9% 14.3% 42.9% • Categorical analysis of DAS28CRP, per protocol, pre - specified a
Slide 19: 104: DAS28 categorical — 6.0 and 12.0 mcg/kg PRTX-100 vs. Placebo
PRTX - 100 - 104: DAS28 categorical -- 6 and 12 mcg/kg PRTX - 100 vs. Placebo 19 DAS28<2.6 DAS28<3.2 Day MTX MTX+SPA MTX MTX+SPA 22 14.3% 14.3% 14.3% 21.4% 29 12.5% 21.4% 12.5% 42.9% 57 25.0% 28.6% 50.0% 50.0% 85 14.3% 28.6% 14.3% 50.0% 113 0.0% 28.6% 14.3% 50.0% • Categorical analysis of DAS28CRP,
Slide 20: 104: CDAI Categorical
PRTX - 100 - 104: CDAI Categorical 20 Day 6.0 & 12.0 mcg/kg All PRTX MTX CDAI <10 n % CDAI <10 n % CDAI <10 n % 22 2 14 14% 3 28 11% 1 7 14% 29 2 13 15% 6 29 21% 1 8 13% 57 4 14 29% 10 28 36% 2 8 25% 85 5 14 36% 7 29 24% 1 7 14% 113 2 10 20% 4 25 16% 0 6 0% CDAI </= 14 for 3 or more consecutive visi
Slide 21: Potential of PRTX-100 as treatment for Immune Thrombocytopenia (ITP)
Potential of PRTX - 100 as treatment for Immune Thrombocytopenia (ITP) Unmet needs exist in ITP ▪ Immune mediated therapies that do not increase risk of infection ▪ Therapies that provide durable responses without continuous treatment ▪ Therapies that are effective in refractory ITP ▪ More conveni
Slide 22: PRTX-100 in ITP: Study Overview
PRTX - 100 in ITP: Study Overview A proposed Phase 1/2, Open - Label, Single Arm Dose Ranging Study Patient Population: ▪ Adult patients with persistent/chronic immune thrombocytopenia (ITP) ▪ Failed at least 1 prior ITP treatment ▪ Platelet count < 30,000/µL including patients on corticosteroid
Slide 23: Patents and Intellectual Property
Patents and Intellectual Property Patents (five issued in US and one in Japan) ▪ Initial US patent 7,211,258, “Protein A compositions and methods of use” filed 2002 and issued 2007 for RA, juvenile RA, and systemic lupus erythematosus ▪ Continuation patents expanding use were issued for: o ITP or
Slide 24: Protalex Objectives
Protalex Objectives x 2Q13 Safety data from first three cohorts of PRTX - 100 - 104 x 3Q13 Initiation of cohort 5 extension study, to investigate monthly maintenance doses x 2Q14 Top - line results of PRTX - 100 - 104 trial □ 3Q14 Filing IND for PRTX - 100 in orphan indication □ 4Q14 Top - line resu
Slide 25: Protalex Investment Highlights
Protalex Investment Highlights PRTX - 100 is a novel immunomodulatory biological drug candidate that may be useful in the treatment of a variety of autoimmune diseases PRTX - 100 is safe and well - tolerated in humans Validated manufacturing process; low cost of goods relative to other biologi